BrightSpring Health Services, Inc. Common Stock Q2 2026 Earnings Recap

BrightSpring’s shares declined sharply by 17% following the report, primarily reflecting investor disappointment with the cautious outlook and impact from exit of certain skilled nursing customers, which weighed on segment growth and margin outlook.

Key Takeaways

• Total revenue grew 23% year-over-year to $3.9 billion, with adjusted EBITDA up 44% to $206 million.
• Pharmacy Solutions revenue increased 22% to $3.4 billion, driven by strong branded oncology LDD portfolio and specialty scripts up 31%, but generic script contribution tempered.
• Home and Community Pharmacy segment was negatively affected by the exit of skilled nursing customers, impacting volume and revenue despite improved profitability from operational efficiencies.
• Provider Services revenue rose 30% to $466 million with adjusted EBITDA up 33%, fueled by Home Health care volume growth, acquisitions, and strong quality metrics, yet integration risks remain.
• Management highlighted opportunities ahead but took a cautious tone on growth and margins, contributing to negative investor reaction.